Race Oncology (ASX:RAC) Discovers RCDS1 Mechanism of Action
Race Oncology (ASX:RAC) announces the discovery of RCDS1’s primary anticancer mechanism, enhancing its clinical and commercial potential.
Category: ASX-RAC
Race Oncology Ltd
Race Oncology Ltd (ASX:RAC) Initiates Phase 1 RC220 + Doxorubicin Trial
Race Oncology (ASX:RAC) safely doses first patient in Phase 1 RC220 + Doxorubicin trial, advancing solid tumour treatments.
Race Oncology (ASX:RAC) Announces Safe Dosing of First Patient in Phase 1 RC220 Trial
Race Oncology (ASX:RAC) successfully dosed the first patient in the Phase 1 RC220 trial for advanced solid tumours, marking a key milestone.
Race Oncology (ASX:RAC) Activates First Australian Clinical Site for RC220 Trial
Race Oncology (ASX:RAC) initiates its first Australian clinical site for the Phase 1 RC220 trial, marking a significant step in advancing cancer treatment.